Urogen Pharma (URGN) News Today $19.44 -0.34 (-1.72%) Closing price 04:00 PM EasternExtended Trading$19.56 +0.11 (+0.59%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period UroGen Pharma to Present at Upcoming Investor ConferencesAugust 21 at 8:00 AM | globenewswire.comFox Run Management L.L.C. Takes Position in Urogen Pharma $URGNAugust 21 at 4:08 AM | marketbeat.comPiper Sandler Initiates Coverage of UroGen Pharma (URGN) with Overweight RecommendationAugust 20 at 4:14 AM | msn.comPiper starts ‘underestimated’ UroGen Pharma with an OverweightAugust 19 at 1:11 PM | msn.comUroGen Pharma initiated with an Overweight at Piper SandlerAugust 18, 2025 | msn.comUroGen Pharma: Targeting Profits In 2027August 18, 2025 | seekingalpha.comOak Ridge Investments LLC Has $815,000 Position in Urogen Pharma (NASDAQ:URGN)August 17, 2025 | marketbeat.comQ3 EPS Estimates for Urogen Pharma Reduced by HC WainwrightAugust 16, 2025 | marketbeat.comHC Wainwright Has Weak Outlook for Urogen Pharma Q3 EarningsAugust 16, 2025 | americanbankingnews.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 SharesAugust 15, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 14, 2025 | marketbeat.com17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners LtdAugust 13, 2025 | marketbeat.comUroGen Pharma’s Earnings Call: Achievements and ChallengesAugust 13, 2025 | msn.comUrogen Pharma (NASDAQ:URGN) Receives Average Rating of "Buy" from BrokeragesAugust 13, 2025 | americanbankingnews.comUroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comHC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock PriceAugust 12, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPSAugust 11, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their EstimatesAugust 10, 2025 | finance.yahoo.comUroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comUroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call PresentationAugust 9, 2025 | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak EarningsAugust 8, 2025 | marketbeat.comUroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...August 8, 2025 | finance.yahoo.comUroGen Pharma Reports Q2 2025 Results and Launches ZUSDURIAugust 8, 2025 | tipranks.comUroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beatAugust 7, 2025 | investing.comUroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beatAugust 7, 2025 | investing.comUrogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara BancroftAugust 7, 2025 | tipranks.comUroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comUroGen Pharma Q2 2025 Earnings PreviewAugust 6, 2025 | msn.comD. Boral Capital Reaffirms Buy Rating for Urogen Pharma (NASDAQ:URGN)August 6, 2025 | marketbeat.comUroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade ...August 6, 2025 | finance.yahoo.comUrogen Pharma (NASDAQ:URGN) Sets New 1-Year High - Should You Buy?August 5, 2025 | marketbeat.comUroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerAugust 5, 2025 | globenewswire.comPrivium Fund Management B.V. Has $1.19 Million Stock Position in Urogen Pharma (NASDAQ:URGN)August 3, 2025 | marketbeat.comJefferies Financial Group Inc. Lowers Holdings in Urogen Pharma (NASDAQ:URGN)August 1, 2025 | marketbeat.comMark Schoenberg Sells 5,149 Shares of Urogen Pharma (NASDAQ:URGN) StockJuly 31, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) General Counsel Sells $143,971.08 in StockJuly 31, 2025 | marketbeat.comInsider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells 5,149 Shares of StockJuly 31, 2025 | insidertrades.comUrogen Pharma (URGN) Projected to Post Earnings on ThursdayJuly 31, 2025 | marketbeat.comUroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025July 29, 2025 | globenewswire.comUrogen Pharma (NASDAQ:URGN) Reaches New 12-Month High - Still a Buy?July 29, 2025 | marketbeat.comUroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical OncologyJuly 29, 2025 | finance.yahoo.comUROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action LawsuitJuly 28, 2025 | globenewswire.comUroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in UrologyJuly 28, 2025 | globenewswire.comARK Investment Management LLC Purchases 45,642 Shares of Urogen Pharma (NASDAQ:URGN)July 27, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Shares Up 9.8% - Still a Buy?July 23, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Reaches New 52-Week High - Time to Buy?July 23, 2025 | marketbeat.comUROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action LawsuitJuly 21, 2025 | globenewswire.comINVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of July 28, 2025 Lead Plaintiff Deadline in the UroGen Pharma Ltd. (URGN) Class Action – Investors With Significant Losses Encouraged to Contact the FirmJuly 21, 2025 | globenewswire.com3 Bullish Biotech Stocks With Explosive Growth Trends (URGN)These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies...July 21, 2025 | marketbeat.comUroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerJuly 21, 2025 | globenewswire.com Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Videos URGN Media Mentions By Week URGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼0.240.54▲Average Medical News Sentiment URGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼1012▲URGN Articles Average Week Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Lantheus News Today MoonLake Immunotherapeutics News Today Protagonist Therapeutics News Today Metsera News Today Mirum Pharmaceuticals News Today Apellis Pharmaceuticals News Today Scholar Rock News Today Xenon Pharmaceuticals News Today Amneal Pharmaceuticals News Today MorphoSys News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle, Microsoft, IBM… every major AI player will be forced to secure massive amounts of this material just t...True Market Insiders | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access